James Davis on Muck Rack

James Davis

Florida
As seen in: CNN, Medium, Color Research & Application, Nature, TIME, USA Today, Wiley Online Library, Bandcamp Daily, New York Daily News, Review of Educational Research and
Religion reporter for Sun Sentinel, Ft. Lauderdale; evangelical Christian, jazz-fusion diehard, digital photography enthusiast, Lord of the Rings geek.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with James

Contact James, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

|
By Andrew J. Portuguese, James Davis, Shahzad Raza, Omar Castaneda Puglianini, Ciara L Freeman, Melissa Alsina, Corbin Wright, Brandon Blue, Rachid Baz, Kenneth H Shain, Utkarsh Goel, Jack Khouri, Faiz Anwer, Hossam Ali, Oren Pasvolsky, Mahmoud R. Gaballa, Damian Mikulski, Lindsay Fogel, Eli Zolotov, Aishwarya Sannareddy, Aimaz Afrough, Larry D. Jr, Kelley Julian, Danai Dima, Rahul Banerjee, Emily Liang, Raffaella Cassano, Megan Herr , Hamza Hassan, Leyla O. Shune, Jeries Kort, Shonali Midha, Omar Nadeem, Surbhi Sidana, Yi Lin, Frederick Locke, Doris Hansen, Douglas Sborov, Noa Biran, Ariel Grajales-Cruz, Hector Garcia-Pleitez
| Nature
Abstract Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies.
Open in Who Shared Issue with article?

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium

|
By CINDY varga, Myra Robinson, James Davis, Hamza Hashmi, Thomas Martin, Anupama Kumar, Douglas Sborov, Charlotte Wagner, Doris Hansen, Omar Castaneda Puglianini, Leyla O. Shune, Aimaz Afrough, Larry D. Jr, Binod Dhakal, Megan Herr , Shambavi Richard, Alex Lieberman-Cribbin, Daniel W. Sherbenou, Peter Forsberg, Sneha Purvey, Jack Khouri, Yi Lin, Surbhi Sidana, Shonali Midha, Christopher J. Ferreri, Evgeunia Bhurtel, Mehmet Kocoglu
| Nature
Abstract Prolonged cytopenias are a well-recognized complication following CAR-T therapy. Autologous SCB offers a potential strategy to promote fast hematologic recovery. We conducted a retrospective multi-institutional comparing outcomes of SCB versus supportive care alone in patients with prolonged cytopenias after CAR-T infusion. Patients were included if they received SCB within 1 year following commercial CAR-T between 6/2021 and 3/2024.
Open in Who Shared Issue with article?

Corallizoanthus aureus Kise, Bessho-Uehara, Kondo, Shimoji, Ito, Tsuchida, Fujiwara & Reimer, 2025

|
By James Davis
| Marinespecies
Description External morphology. Polyps found on all over the surface of Pleurocorallium inutile Kishinouye, 1903. Some polyps unitary,... Distribution Corallizoanthus aureus sp. nov. has been found only on Pleurocorallium inutile, at depths of 245−400 m, from Tanegashima... Etymology The specific name derives from ‘aureus’ meaning ‘golden’ in Latin.
Open in Who Shared Issue with article?
See all 133 licensed articles (134 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with James

Contact James, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified